EBAMed raised EUR 1.6 Million
Share this article
The Geneva-based company has just secured a further EUR 1.6 Million from CDP Venture Capital and the European Union. This brings the total amount raised in the series A financing round to EUR 16 Million.
EBAMed, is a Geneva-Based start-up developing a guidance system for the non-invasive treatment of heart arrhythmias through Proton Therapy.
“Our deepest gratitude goes to CDP Venture Capital and the European Union for their confidence in our vision and their vital support. This investment propels us forward in our mission to build innovative healthcare solutions that improve people’s health and strengthen the healthcare system, making it more prepared and sustainable to face future challenges.” says CEO Marina Izzo.
In June 2023, EBAMed announced a 14.35 M € in Series A Funding to bring its CardioKit system up to the completion of its First in Human trials. The financing round was led by Panakès Partners, a venture capital firm with headquarters in Milan, together with the EIC Fund, Swiss EFI Lake Geneva Ventures, LIFTT Venture Capital Italia, and OCCIDENT. The round was also supported by existing investors, including Mayo Clinic.
Heart arrhythmias affect around 50 million individuals worldwide and are expected to grow in the next 50 years as the population ages. Ventricular arrhythmias affect the lower chambers of the heart and consist primarily of ventricular tachycardias, or VTs, and premature ventricular contractions, or PVCs. EBAMed’s CardioKit system is used for a non-invasive treatment of Ventricular Tachycardia through Proton Therapy. It automatically adjusts cardiac radiation ablation systems for cardiac motion and increases external beam delivery precision. The development of a radiation therapy approach, combined with a unique motion monitoring and gating solution, will fill an important need for alternatives to either drug therapy or catheter-based ablation, and for reduced radiation of healthy myocardium.
Source: PR.